Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis

Published:2024-08 Issue: Volume:126 Page:77-82
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Sun Xiaochuan^ORCID,Fang Chenglong,Jin Shangyi,Li Jing,Yang Yunjiao,Zeng Xiaofeng,Tian Xinping^ORCID

Publisher

Elsevier BV

Reference18 articles.

1. Large-vessel vasculitis;Pugh;Nat Rev Dis Primers,2022

2. The critical role of IL-6 in the pathogenesis of Takayasu arteritis;Kong;Clin Exp Rheumatol,2016

3. Interleukin 6: from bench to bedside;Nishimoto;Nat Clin Pract Rheumatol,2006

4. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis;Kang;Front Immunol,2023

5. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses;Berger;Ann Rheum Dis,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study;Annals of Oncology;2024-09

2. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study;2024-07-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP